Table 1.
Characteristics of patients
| Total N = 279 | |
|---|---|
| Number of patients (%) | |
| Age at diagnosis, median (range years) | 55 (25 – 95) |
| Duration of tamoxifen treatment, median (range months) | 21.5 (1 – 70) |
| Tamoxifen therapy | |
| neoadjuvant | 7 (2.5) |
| adjuvant | 258 (92.5) |
| metastasis | 14 (5) |
| Breast cancer treatment | |
| surgery | 276 (98.9) |
| received radiation | 148 (53) |
| received chemotherapy | 232 (83.2) |
| Hormonal status at diagnosis | |
| premenopausal | 81 (29) |
| postmenopausal | 115 (41.2) |
| unknown | 83 (29.7) |
| Tumor size | |
| T1 | 105 (37.6) |
| T2 | 142 (50.9) |
| T3 | 20 (7.2) |
| T4 | 10 (3.6) |
| unknown | 2 (0.7) |
| Node status | |
| N 0 | 132 (47.3) |
| N 1 | 112 (40.3) |
| N 2 - 3 | 30 (10.8) |
| unknown | 5 (1.8) |
| Differential grade | |
| G1 | 39 (14) |
| G2 | 129 (46.2) |
| G3 | 67 (24) |
| unknown | 44 (15.8) |
| Histology | |
| ductal | 205 (73.5) |
| lobular | 30 (10.8) |
| other | 38 (13.6) |
| unknown | 6 (2.2) |
| Hormone receptor status | |
| Estrogen+ | 269 (96.4) |
| Progesterone+ | 238 (85.3) |
| Both | 230 (82.4) |
| HER2 status | |
| positive | 64 (22.9) |
| negative | 210 (75.3) |
| unknown | 5 (1.8) |
Tumor characteristics were at diagnosis. HER2: human epidermal growth factor receptor 2